Skip to main content

Table 2 Quality of life, depression, daytime sleepiness, sleep quality and RLS symptom’s severity data divided in three groups divided in three groups according to the assigned intervention

From: Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study

Variables

Exercise group

Dopamine agonists group

Placebo group

Sleep Diary

   

Baseline

7.69±5.51

10.28±2.87

8.42±5.09

6-m post

7.30±4.13

5.85±3.71†

8.85±4.09

Δ Change

−0.71±3.22

- 4.42±3.10#¶

0.42±2.7

95% CI of Δ change

−2.49 to 1.07

−7.28 to −1.56

2.91 to −2.07

Epworth Sleepiness Scale

   

Baseline

5.15±2.54

7.85±5.24

8.71±5.37

6-m post

5.15±2.47

5.42±1.98

8.42±4.92

Δ Change

−0.35±2.73

−2.42±5.38

- 0.28±4.19

95% CI of Δ change

−1.85 to 1.15

−7.39 to 2.55

−4.15 to 3.59

Zung Depression Scale

   

Baseline

43.45±8.06

46.85±13.49

37.85±12.15

6-m post

35.84±6.38†#

39.42±4.35

43.71±11.17†¶

Δ Change

−8.28±7.91#

−7.42±10.34#

5.85±6.41

95% CI of Δ change

−12.60 to −3.91

−16.96 to 2.12

11.70 to −0.07

IRLS score

   

Baseline

25.14±9.09

24.14±5.55

19.71±7.49

6-m post

13.42±11.28†

11.57±7.84†

18.57±10.65

Δ Change

−13.12±8.59#

- 12.57±5.31#

- 1.14±8.43

95% CI of Δ change

−17.87 to −8.37

−17.47 to −7.67

−8.93 to 6.65

SF-36 MCS score

   

Baseline

61.1±22.0

39.1±23.8

68.1±19.1

6-m post

70.4±18.7

63.0±17.0†

65.0±21.9

Δ Change

9.3±26.7

23.8±14.1

3.1±9.8

95% CI of Δ change

24.1 to 5.4

36.9 to 10.7

5.9 to −12.2

SF-36 PCS score

   

Baseline

64.9±18.6

48.7±21.0

64.4±22.5

6-m post

76.4±15.6†

68.8±19.2†

70.5±26.5

Δ Change

11.5±18.4

20.1±6.0

6.1±5.7

95% CI of Δ change

21.7 to 1.2

25.7 to 14.5

20.2 to −7.9

  1. All data are mean ± SD. Abbreviations: IRLS International restless legs syndrome severity scale, SF-36 Self reported quality of life questionnaire, MCS Mental component summary, PCS Physical component summary.
  2. #Significantly different than placebo group.
  3. ¶Significantly different than exercise group.
  4. †Significantly different from the respective baseline value.